We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-1.29%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$2.33B
AUM Growth
+$549M
Cap. Flow
+$131M
Cap. Flow %
5.6%
Top 10 Hldgs %
56.72%
Holding
316
New
83
Increased
72
Reduced
72
Closed
65

Top Buys

Rank Stock Value
1
WY icon
Weyerhaeuser
WY
+$59M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$33.1M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$9.18M
4
AGN
Allergan plc
AGN
+$6.91M
5
CNSY
Cerenome
CNSY
+$6.73M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$12.1M
2
BPTH
Bio-Path Holdings Inc
BPTH
+$8.78M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$7.12M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$6.23M
5
TMO icon
Thermo Fisher Scientific
TMO
+$4.64M

Sector Composition

Rank Sector Weight
1 Miscellaneous 86.57%
2 Healthcare 9.72%
3 Real Estate 2.82%
4 Energy 0.36%
5 Consumer Discretionary 0.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATHX
226
PUT
DELISTED
Athersys, Inc. Common Stock
ATHX
$207K 0.01%
46
+4
+10% +$197
ARNA
227
CALL
DELISTED
Arena Pharmaceuticals Inc
ARNA
$179K 0.01%
+31
New +$1.95K
ARIA
228
CALL
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$165K 0.01%
259
-6,961
-96% -$47.9K
ACHV icon
229
CALL
Achieve Life Sciences
ACHV
$729M
– –
0
– –
FOCL
230
PUT
EDAP TMS S.A.
FOCL
$190M
$162K 0.01%
+326
New +$1.12K
ACGN
231
CALL
DELISTED
Aceragen Inc
ACGN
– –
0
– –
EYPT icon
232
CALL
EyePoint Inc
EYPT
$352M
$152K 0.01%
35
+25
+250% +$942
NBIX icon
233
PUT
Neurocrine Biosciences
NBIX
$15.6B
$148K 0.01%
100
– –
STAB
234
DELISTED
Statera Biopharma, Inc. Common Stock
STAB
$147K 0.01%
15,308
-76,000
-83% -$888K
ANTH
235
CALL
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$138K 0.01%
51
+11
+28% +$272
CGEN icon
236
CALL
Compugen
CGEN
$231M
$135K 0.01%
150
-1,137
-88% -$10.2K
PLUR icon
237
Pluri
PLUR
$15.4M
$125K 0.01%
499
-2,668
-84% -$734K
AGEN
238
PUT
Agenus
AGEN
$309M
$79K ﹤0.01%
12
– –
CASC
239
CALL
DELISTED
Cascadian Therapeutics, Inc.
CASC
$76K ﹤0.01%
39
-46
-54% -$812
OXGN
240
CALL
DELISTED
OXIGENE INC COM
OXGN
$71K ﹤0.01%
+275
New +$802
CRDF icon
241
Cardiff Oncology
CRDF
$110M
$70K ﹤0.01%
278
– –
ADXS
242
DELISTED
Advaxis Inc
ADXS
$60K ﹤0.01%
+1,267
New +$55.2K
PGNX
243
PUT
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$50K ﹤0.01%
117
-181
-61% -$691
ADXSW
244
DELISTED
Advaxis Inc Warrants
ADXSW
$46K ﹤0.01%
45,354
-99,581
-69% -$103K
ALBO
245
PUT
DELISTED
Albireo Pharma Inc
ALBO
$39K ﹤0.01%
6
– –
GERN icon
246
PUT
Geron
GERN
$867M
$34K ﹤0.01%
+113
New +$236
ATHX
247
CALL
DELISTED
Athersys, Inc. Common Stock
ATHX
$30K ﹤0.01%
7
-17
-71% -$837
SEEL
248
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
– –
0
– –
IMUC
249
PUT
DELISTED
ImmunoCellular Therapeutics, Ltd.
IMUC
$22K ﹤0.01%
5
-55
-92% -$2.65K
CVM icon
250
CEL-SCI Corp
CVM
$26.4M
$16K ﹤0.01%
17
– –
8 9
10
11 12

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q2 2014 Portfolio in Review

As of Q2 2014, Sabby Management held 316 positions worth $2.33B, up 31% from $1.78B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Sabby Management deployed $131M of net new capital in Q2 2014, opening 83 new positions and adding to 72 existing holdings. Its largest new stake was Weyerhaeuser: 1,950,977 shares worth $64.6M.

By sector, the portfolio is most concentrated in Miscellaneous at 87% of assets, down from 89% a quarter earlier, followed by Healthcare and Real Estate.

On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $7.12M trimmed.

  • Sabby Management's largest Q2 2014 buy was Weyerhaeuser: 1,950,977 shares worth $64.6M.
  • Sabby Management added most to Teva Pharmaceuticals in Q2 2014, an estimated $33.1M increase.
  • Sabby Management's biggest Q2 2014 reduction was Sarepta Therapeutics, cutting an estimated $7.12M.
  • Sabby Management fully exited Gilead Sciences in Q2 2014, selling an estimated $12.1M.
  • Sabby Management's ten largest holdings make up 57% of its $2.33B portfolio in Q2 2014.
  • Sabby Management opened 83 new positions and closed 65 in Q2 2014.
  • Sabby Management's portfolio value rose 31% quarter-over-quarter to $2.33B.

Based on Sabby Management's 13F filing for Q2 2014, filed 14 Aug 2014.